title: A review of the history, properties, and use of the immunomodulatory compound lenalidomide.
abstract: Lenalidomide (REVLIMID), an immunomodulatory compound targeting both cancer cells and their microenvironment, has substantial activity in several difficult-to-manage hematological malignancies. In previously treated multiple myeloma, lenalidomide produces high-quality responses combined with sustained disease control. Recently, several randomized studies have demonstrated a clinical benefit of continuous lenalidomide treatment in newly diagnosed multiple myeloma. In many patients with refractory anemia associated with lower risk myelodysplastic syndromes and a 5q chromosome deletion, lenalidomide leads to transfusion independence, considerably improving quality of life. It has a manageable safety profile, and its oral formulation reduces the burden on patients. Several phase III trials are ongoing in other indications currently underserved by conventional therapy, such as chronic lymphocytic leukemia, non-Hodgkin's lymphoma, and prostate cancer. Several early-stage studies are exploring lenalidomide alone and in combination across different hematological malignancies, solid tumors, and immune-related disorders.
authors: Celgene Corporation, Summit, New Jersey, USA. jzeldis@celgene.com
authors: Jerome B
authors: JB
authors: Zeldis
authors: Robert
authors: R
authors: Knight
authors: Mohamad
authors: M
authors: Hussein
authors: Rajesh
authors: R
authors: Chopra
authors: George
authors: G
authors: Muller
mesh_terms: D055808:Drug Discovery / Q000266:history / Q000639:trends; D049673:History, 20th Century; D049674:History, 21st Century; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects / Q000138:chemical synthesis / Q000494:pharmacology* / Q000627:therapeutic use*; D000077269:Lenalidomide; D008954:Models, Biological; D009369:Neoplasms / Q000188:drug therapy / Q000276:immunology; D013792:Thalidomide / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000138:chemical synthesis / Q000494:pharmacology / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D007155:Immunologic Factors; D013792:Thalidomide; D000077269:Lenalidomide